ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
Retrieved on:
Thursday, September 28, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Topotecan, European Society of Gynaecological Oncology, Pros, Bevacizumab, University, Progression-free survival, Neoplasm, Catholic University of Leuven (1834–1968), OS, IC, Cancer, Paclitaxel, PLD, ESGO, PFS, University Clinical Centre in Gdańsk, Mirvetuximab soravtansine, IMGN, PROC, ASCO, Congress, Ventana, American Society of Clinical Oncology, Patient, Physician, TYPE, Annual general meeting, CRS, Spacecraft, GOG, PARP, Society, ORR, Safety, Pharmaceutical industry, Medical imaging
Patients were stratified by number of prior lines of therapy (14% had one prior line of therapy, 40% had two prior lines of therapy, and 46% had three prior lines of therapy) and by IC chemotherapy, with paclitaxel as the most commonly chosen (41%), followed by PLD (36%) and topotecan (23%).
Key Points:
- Patients were stratified by number of prior lines of therapy (14% had one prior line of therapy, 40% had two prior lines of therapy, and 46% had three prior lines of therapy) and by IC chemotherapy, with paclitaxel as the most commonly chosen (41%), followed by PLD (36%) and topotecan (23%).
- 62% of patients received prior bevacizumab; 55% received a prior PARP inhibitor.
- Key secondary endpoints include objective response rate (ORR), overall survival (OS), and patient-reported outcomes (PROs).
- ELAHERE demonstrated clinically meaningful improvements in PFS and ORR by investigator assessment and in OS compared to IC chemotherapy, regardless of prior lines of therapy (PLOT).